<DOC>
	<DOCNO>NCT01361607</DOCNO>
	<brief_summary>This 9-week study aim determine efficacy , safety tolerability Sativex® ( Nabiximols ) adjunctive treatment , compare placebo relieve uncontrolled persistent chronic pain patient advance cancer . Eligible patient require stop current treatment medication .</brief_summary>
	<brief_title>Sativex® Relieving Persistent Pain Patients With Advanced Cancer</brief_title>
	<detailed_description>This 9-week , multi-center , double-blind , randomize , placebo-controlled study aim determine efficacy , safety tolerability Sativex administer adjunctive treatment 5 week , vs. placebo . Eligible patient advanced cancer , clinical diagnosis cancer relate pain wholly alleviate current optimized opioid treatment . Qualifying patient enter study Visit 1 commence 5-14 day eligibility period . During period , eligible patient 3 consecutive day pain severity remain within defined parameter , break-through opioid usage exceed average 4 episode per day , maintenance opioid medication dose change . Eligible patient return randomization visit ( Visit 2 , Day 1 ) randomize either Sativex placebo use 1:1 allocation ratio . Patients begin initial titration period last 14 day ; titration schedule require dose minimum 3 spray per day , patient allow individualize dose ( 3-10 spray per day ) Day 14 , dose fix remainder study . Patients return Visit 3 ( Day 22 ) Visit 4 ( Day 36 , end randomize treatment period ) , earlier terminate prematurely study . After end 5-week treatment period , patient offer option enter open-label extension ( OLE ) study ; safety follow visit ( Visit 5 ) require patient entered OLE day Visit 4 . Patients enter OLE 7 day Visit 4 Visit 5 assessment perform day first OLE study visit . Patients enter OLE study safety follow visit ( Visit 5 ) 14 day treatment completion , could via telephone .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Analgesics , Opioid</mesh_term>
	<criteria>Inclusion Criteria ( abbreviate ) : The patient advance cancer know curative therapy The patient clinical diagnosis cancer relate pain , alleviate current optimized opioid treatment The patient receive optimized maintenance dose Step III opioid therapy , preferably sustain release preparation , also allow regular maintenance dose around clock use immediate release preparation The patient receive daily maintenance dose Step III opioid therapy less equal total daily opioid dose 500 mg/day morphine equivalence ( include maintenance breakthrough opioids ) The patient use one type breakthrough opioid analgesia Exclusion Criteria ( abbreviate ) : Have plan clinical intervention would affect pain ( e.g. , chemotherapy radiation therapy , clinical judgment investigator , would expect affect pain ) The patient currently use use cannabis cannabinoid base medication within 30 day study entry unwilling abstain duration study Has experience myocardial infarction clinically significant cardiac dysfunction within last 12 month cardiac disorder , opinion investigator would put patient risk clinically significant arrhythmia myocardial infarction Has significantly impair renal function Has significantly impair hepatic function Female patient childbearing potential male patient whose partner childbearing potential , unless willing ensure partner use effective contraception , example , oral contraception , double barrier , intrauterine device , study three month thereafter ( however , male condom use conjunction female condom may prove effective )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Cancer pain</keyword>
	<keyword>Opioid therapy</keyword>
	<keyword>Inadequate analgesia</keyword>
	<keyword>Optimized chronic opioid therapy</keyword>
</DOC>